Instruction 1(b)

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **OMB APPROVAL** OMB Number: Estimated average burden

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HOUGEN ELIZABETH L  (Last) (First) (Middle)  C/O ISIS PHARMACEUTICALS, INC.  2855 GAZELLE COURT					Issuer Name and Ticker or Trading Symbol     ISIS PHARMACEUTICALS INC [ ISIS ]      Date of Earliest Transaction (Month/Day/Year) 01/02/2013							Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director			
(City) (State) (Zip)				_	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applic Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person  tive Securities Acquired, Disposed of, or Beneficially Owned										on
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					ction 2A. Deemed Execution Date,			3. Transacti Code (Ins	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		ed (A) or tr. 3, 4 and	5. Amount of Securities Beneficially		5. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Table II - Der (e.g 3A. Deemed Execution Date, if any (Month/Day/Yea	4. Transaction Code (Instr		5. Number			convert		d Amount ies	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right to buy)	\$10.82	01/02/2013	01/02/2013	A		7,500		(1)	01/01/2020	Common Stock	7,500	\$0	7,500	D	
Employee Stock Option (right to	\$10.82	01/02/2013	01/02/2013	A		15,700		(2)	01/01/2020	Common Stock	15,700	\$0	15,700	D	

## **Explanation of Responses:**

- 1. Grant of 1/2/13 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/14. Thereafter, the remaining shares subject to the option vest and become exerciable in 36 equal monthly installments, at the rate of 1,875 shares per year. The option is exercisable as to 0 on 1/1/13.
- 2. Grant of 1/2/13 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/14. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 3,925 shares per year. The option is exercisable as to 0 on 1/2/13.

## Remarks:

/s/Elizabether L. Hougen \*\* Signature of Reporting Person 01/02/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.